MedTrace Logo

Study to Assess the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of AZD3043

NCT00918515 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2009-08-28

No results posted yet for this study

Summary

This is a Phase I, single centre, open label study to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics of intravenous AZD3043 after single ascending doses in healthy male volunteers.

Conditions

  • Healthy

Interventions

DRUG

AZD3043

intravenous solution given once as intravenous infusion over 30 minutes

Sponsors & Collaborators

Principal Investigators

  • Johan Wemer · AstraZeneca R&D Södertälje

  • Sigridur Kalman · Department of Clinical Science Intervention and technology, CLINTECThe department of Anaesthosiology and Intensive care, Karolinska University hospital, Huddinge,141 86 Stockholm, Sweden

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-05-31
Completion
2009-08-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00918515 on ClinicalTrials.gov